Open-label, multicenter safety study of vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma

被引：0

作者：

Larkin, James M. G.

Del Vecchio, Michele

Ascierto, Paolo Antonio

Schachter, Jacob

Garbe, Claus

Neyns, Bart

Mandala, Mario

Lorigan, Paul

Miller, Wilson H.

Guminski, Alexander David

Berking, Carola

Rutkowski, Piotr

Queirolo, Paola

Hauschild, Axel

Arance, Ana Maria

Brown, Michael Paul

Mitchell, Lada

Veronese, Maria Luisa

Blank, Christian U.

机构：

[1] Royal Marsden Hosp NHS Fdn Trust, London, England

[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[3] Ist Nazl Tumori Fdn, Naples, Italy

[4] Chaim Sheba Med Ctr, Ella Inst Melanoma, Div Oncol, IL-52621 Tel Hashomer, Israel

[5] Univ Tubingen, Hautklin, Tubingen, Germany

[6] UZ Brussel, Brussels, Belgium

[7] Dept Hematol & Oncol, Div Med Oncol, Unit Clin & Translat Res, Bergamo, Italy

[8] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England

[9] McGill Univ, Jewish Gen Hosp, Lady Davis Inst, Montreal, PQ H3T 1E2, Canada

[10] McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Montreal, PQ H3T 1E2, Canada

[11] Melanoma Inst Australia, Sydney, NSW, Australia

[12] Univ Munich, Dept Dermatol, D-80539 Munich, Germany

[13] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland

[14] Inst Oncol, Warsaw, Poland

[15] Natl Inst Canc Res, Dept Med Oncol A, Genoa, Italy

[16] Univ Hautklin Kiel, Kiel, Germany

[17] Hosp Clin Barcelona, Barcelona, Spain

[18] Royal Adelaide Hosp, Adelaide, SA 5000, Australia

[19] F Hoffmann La Roche Ltd, Basel, Switzerland

[20] Hoffmann La Roche Ltd, Basel, Switzerland

[21] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9046

引用

页数：1